Form 8-K - Current report:
SEC Accession No. 0000950170-25-103543
Filing Date
2025-08-06
Accepted
2025-08-06 07:39:52
Documents
14
Period of Report
2025-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lnth-20250806.htm   iXBRL 8-K 53085
2 EX-99.1 lnth-ex99_1.htm EX-99.1 795921
3 EX-99.2 lnth-ex99_2.htm EX-99.2 39998
4 GRAPHIC img66337839_0.jpg GRAPHIC 19366
5 GRAPHIC img67261360_0.jpg GRAPHIC 36637
  Complete submission text file 0000950170-25-103543.txt   1120159

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lnth-20250806.xsd EX-101.SCH 26007
16 EXTRACTED XBRL INSTANCE DOCUMENT lnth-20250806_htm.xml XML 4941
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)